A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 9, 2023

Primary Completion Date

March 27, 2025

Study Completion Date

April 12, 2025

Conditions
Multiple Sclerosis
Interventions
DRUG

Dimethyl fumarate

Administered as specified in the treatment arm.

Trial Locations (15)

30001

The First Affiliated Hospital of Shanxi Medical University, Taiyuan

100730

Beijing Hospital, Beijing

110002

The First Hospital of China Medical University, Shengyang

200001

Renji Hospital, Shanghai Jiatong Uni. School of Medicine, Shanghai

200040

Huashan Hospital, Fudan University, Shanghai

215004

The First Affiliated Hospital of Soochow University, Suzhou

300052

Tianjin Medical University General Hospital, Tianjin

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

350005

The First Affiliated Hospital of Fujian Medical University, Fuzhou

410008

Xiangya Hospital Central South University, Changsha

510630

The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou

610041

West China Hospital of Sichuan University, Chengdu

650032

The First People's Hospital of Yunnan Province, Kunming

710038

Second Affiliated Hospital of Air Force Medical University, Xi'an

050004

The Second Hospital of Hebei Medical University, Hebei

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY